NEQSOL Holding Recognized Among the Largest Taxpayers in Azerbaijan
In 2024, NEQSOL Holding companies contributed a total of AZN 171.1 million (USD ~ 60 million) in tax payments to the Azerbaijani state budget, solidifying the holding's position as one of the largest taxpayers in the country.
'Along with substantial tax contributions, NEQSOL Holding actively supports Azerbaijan's economic development through sustainable business strategies, long-term investments, job creation, and social initiatives aimed at community well-being. These achievements reaffirm the holding's commitment to transparency, economic growth, and corporate social responsibility,' said Yusif Jabbarov, CEO of NEQSOL Holding.
Among the leading taxpayers within the Holding's portfolio are Norm, Bakcell, Azerconnect Group, Nobel Energy Group (including Global Energy Solutions) and other companies.
About NEQSOL Holding
NEQSOL Holding is an international group of companies operating across 11 countries in telecommunications, energy, construction, and hi-tech industries. The holding places significant emphasis on expanding its presence in Azerbaijan and, as it continues to grow, remains dedicated to contributing to the country's economic and social development. For more information please see: NEQSOL Holding
Media contact: Neqsol@tiltonconsultancy.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
HazardPros Announces Public Awareness Campaign for Death and Decomposition Cleanup Services in Seattle
SEATTLE, Aug. 14, 2025 (GLOBE NEWSWIRE) — HazardPros, a Washington-based biohazard remediation and hoarding cleanup company , has launched a public awareness campaign to inform residents and businesses about its specialized death cleanup and decomposition cleanup services. The effort aims to ensure that property owners know where to turn for professional assistance following traumatic or hazardous events. HazardPros: Biohazard & hoarding cleanup in Seattle. The Seattle team is trained and equipped to provide comprehensive biohazard cleanup that meets or exceeds industry standards. HazardPros technicians handle sensitive situations with discretion, compassion, and strict adherence to health and safety regulations, including OSHA and EPA guidelines. Available services include trauma scene cleanup, crime scene cleanup, hoarding cleanup, unattended death cleanup, odor removal, hazardous waste removal, and blood cleanup. 'Our priority is to respond quickly, handle every situation with care, and restore each property to a safe and sanitary condition,' said Michael Gossett of HazardPros. 'By raising awareness, we want people to know that help is available any time of day or night.' HazardPros operates 24/7, providing emergency response for residential, commercial, and public properties throughout Seattle and surrounding communities. The company uses advanced cleaning agents, proven remediation methods, and specialized equipment to eliminate biohazards, remove odors, and return affected spaces to safe use. In addition to death cleanup and decomposition cleanup, HazardPros offers support for hoarded property remediation, infectious disease decontamination, and complex hazardous waste situations. The team provides clear communication, detailed estimates, and insurance documentation to help clients navigate what is often a stressful and overwhelming process. With this awareness campaign, HazardPros aims to connect with community members, property managers, and business owners to ensure they are informed about professional cleanup options. By combining industry-standard practices with a compassionate approach, HazardPros continues to be a trusted resource for restoring safety and peace of mind in the Seattle area. About HazardPros HazardPros is a Washington-based biohazard remediation company specializing in death cleanup, decomposition cleanup, and other hazardous waste removal services. Serving Seattle and surrounding communities, HazardPros provides 24/7 emergency response, compassionate service, and compliance with all health and safety regulations. Media Contact:Michael Gossett Email: [email protected] Website:
Business Upturn
an hour ago
- Business Upturn
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) — , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor. LIXTE's Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position : Multiple issued and pending patents covering composition, methods of use, and combinations : Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion : Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. : Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact [email protected] for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC Disclaimer Please go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
an hour ago
- Business Upturn
EU Good Food Fruits Add a Fresh Accent to Korea's Culinary Scene
SEOUL, South Korea, Aug. 14, 2025 (GLOBE NEWSWIRE) — EU Good Food has officially introduced premium European kiwis and canned peaches to Korean consumers, marking an important milestone in its collaboration with the Korean market. This launch highlights the initiative's long-term commitment to delivering high-quality, fully traceable European ingredients to Korea's food industry and households. European kiwis and canned peaches, sourced from the Mediterranean region, bring a fresh and flavour-rich dimension to Korean dining. More than just snacks or dessert ingredients, these fruits combine exceptional flavour, texture, and natural balance – making them ideal additions to a wide variety of Korean dishes. A Fresh Accent to Korean Plates Celebrated for their quality and flavour, European kiwis and canned peaches bring a pleasant harmony and creative highlights to Korean cuisine. European kiwis offer a distinctive gentle tartness and naturally active enzymes, making them highly versatile for both sweet and savoury applications. They elevate fruit salads and desserts, while also providing a refreshing counterpoint in traditional dishes. When incorporated into naengmyeon, for instance, the crisp tang of kiwi delivers a clean, invigorating twist that complements the dish's signature flavours. Similarly, European canned peaches offer a mellow sweetness and smooth, velvety texture, making them an ideal ingredient for pancakes, butter tarts, and griddled hotteok. When paired with iced Americano, their rich flavour harmonises with the coffee's bitterness, creating a balanced and indulgent treat. Taste with Integrity – Backed by EU Standards What sets these fruits apart is the assurance of quality under EU Good Food. Cultivated, harvested, and packaged according to strict EU regulations, they are fully traceable from orchard to packaging. European farmers prioritise soil health, minimise synthetic inputs, and protect natural ecosystems. This dedication to quality is evident in each fruit. European kiwis are carefully harvested at peak ripeness. This ensures optimal texture, a balanced sweet-tart flavour, and excellent durability during transport and storage. The result is a fruit that maintains its freshness and appeal long after it leaves the orchard. Similarly, peaches are picked only at full maturity and preserved without unnecessary additives. Thanks to clean, modern processing techniques, canned peaches retain their natural juiciness, aroma, and velvety texture. Beyond flavour and freshness, both kiwis and peaches are naturally rich in vitamin C, potassium, and dietary fibre. Their clean-label profile aligns with Korea's growing demand for minimally processed, additive-free products. The official EU certification ensures that every product meets rigorous safety, quality, and consistency standards. Grown with care and packed with goodness, European kiwis and canned peaches bring freshness, flavour, and essential nutrients to Korean tables. Since its introduction to Korea, the EU Good Food campaign has made a significant impact through a series of targeted and high-profile activities. From immersive tasting events at Seoul Food & Hotel to strategic networking initiatives connecting EU suppliers with Korean buyers – including renowned chefs, importers, and key industry stakeholders – the campaign has actively fostered meaningful exchange and long-term collaboration. It has also showcased how seamlessly European products can be integrated into the Korean culinary landscape. Whether featured in intimate family dinners or innovative fusion menus, these fruits bring a refined and flavourful touch to the season. With their bright and rich taste, European kiwis and canned peaches are a natural choice – equally suited for passionate home cooks looking to elevate everyday meals with superior ingredients, and for culinary professionals aiming to craft truly distinctive dining experiences. About EU Good Food EU Good Food is an EU co-funded initiative dedicated to promoting high-quality, safe, and fully traceable European agricultural products worldwide. Through partnerships with local markets, the campaign connects consumers and industry professionals with certified European ingredients, ensuring taste, transparency, and trust in every product. For more information, please visit: Media contact: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
